Analysis of 142 Northern Chinese patients with peripheral T/NK-cell lymphomas: Subtype distribution, clinicopathologic features, and prognosis

American Journal of Clinical Pathology

Volumn 138, Issue 3, 2012, Pages 435-447

  Ren, Ya Li ^a   Nong, Lin ^a   Zhang, Shuang ^a   Zhao, Jing ^a   Zhang, Xiao Ming ^a   Li, Ting ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Classification; ETS1; NK cell lymphoma; Peripheral T cell lymphoma; T bet

Indexed keywords

KI 67 ANTIGEN; LACTATE DEHYDROGENASE; TRANSCRIPTION FACTOR T BET;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CHINESE; CLINICAL FEATURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T AND NATURAL KILLER CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TUMOR CLASSIFICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84865427020     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPWKJ3GPFRT7GA     Document Type: Article

References (32)

1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124-4130.
2. Xu PP, Wang Y, Shen Y, et al. Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients. Med Oncol. June 27, 2011.
3. Niitsu N, Okamoto M, Nakamine H, et al. Clinicopathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol. 2008;26:152-158.
4. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16:206-214.
5. Ko OB, Lee DH, Kim SW, et al. Clinicopathologic characteristics of T-cell non-Hodgkin's lymphoma: a single institution experience. Korean J Intern Med. 2009;24:128-134.
6. Lu D, Lin CN, Chuang SS, et al. T-cell and NK/T-cell lymphomas in southern Taiwan: a study of 72 cases in a single institute. Leuk Lymphoma. 2004;45:923-928. (Pubitemid 38444668)
7. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
8. Yang DH, Kim WS, Kim SJ, et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant. 2009;15:118-125.
9. Zhang S, Li T, Zhang B, et al. Transcription factors engaged in development of NK cells are commonly expressed in nasal NK/T-cell lymphomas. Hum Pathol. 2011;42:1319-1328.
10. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed:Lyon, France: IARC Press; 2008.
11. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2008;111:4463-4470.
12. Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol. 2009;20:1472-1482.
13. Kim YC, Yang WI, Lee MG, et al. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea. Int J Dermatol. 2006;45:1312-1316. (Pubitemid 44688024)
14. Novelli M, Merlino C, Ponti R, et al. Epstein-Barr virus in cutaneous T-cell lymphomas: evaluation of the viral presence and significance in skin and peripheral blood. J Invest Dermatol. 2009;129:1556-1561.
15. Intlekofer AM, Takemoto N, Wherry EJ, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol. 2005;6:1236-1244. (Pubitemid 43045635)
16. Grenningloh R, Kang BY, Ho IC. Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses. J Exp Med. 2005;201:615-626. (Pubitemid 40289551)
17. Barton K, Muthusamy N, Fischer C, et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity. 1998;9:555-563. (Pubitemid 28499206)
18. Anderson MK, Hernandez-Hoyos G, Diamond RA, et al. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development. 1999;126:3131-3148. (Pubitemid 29378177)
19. Lacorazza HD, Nimer SD. The emerging role of the myeloid Elf-1 like transcription factor in hematopoiesis. Blood Cells Mol Dis. 2003;31:342-350. (Pubitemid 37433875)
20. Showell C, Binder O, Conlon FL. T-box genes in early embryogenesis. Dev Dyn. 2004;229:201-218. (Pubitemid 38036834)
21. Suto A, Wurster AL, Reiner SL, et al. IL-21 inhibits IFN-gamma production in developing Th1 cells through the repression of Eomesodermin expression. J Immunol. 2006;177:3721-3727. (Pubitemid 44359904)
22. Takemoto N, Intlekofer AM, Northrup JT, et al. Cutting edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol. 2006;177:7515-7519. (Pubitemid 44846265)
23. Ye Y, Li T, Zhang B, et al. Amplification and specific expression of T-bet gene in nasal NK/T-cell lymphoma. Leuk Lymphoma. 2007;48:168-173. (Pubitemid 46978636)
24. Tsuchiyama J, Yoshino T, Toba K, et al. Induction and characterization of cutaneous lymphocyte antigen on natural killer cells. Br J Haematol. 2002;118:654-662. (Pubitemid 34994678)
25. Alon R, Rossiter H, Wang X, et al. Distinct cell surface ligands mediate T lymphocyte attachment and rolling on P and E selectin under physiological flow. J Cell Biol. 1994;127:1485-1495. (Pubitemid 24362578)
26. Chang ST, Liao YL, Lin SH, et al. NK-cell lymphoma with nodal presentation and expression of cutaneous lymphocyte-associated antigen. Pathol Res Pract. 2010;206:463-466.
27. Magro CM, Dyrsen ME. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. J Cutan Pathol. 2008;35:1040-1049.
28. Yoshino T, Nakamura S, Suzumiya J, et al. Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma. Br J Haematol. 2002;118:482-487. (Pubitemid 34994653)
29. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998;92:76-82. (Pubitemid 28303178)
30. Kim YR, Kim JS, Kim SJ, et al. Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. J Hematol Oncol. 2011;4:34.
31. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472-2479. (Pubitemid 46630624)
32. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474-2479. (Pubitemid 38392996)